Affigen Relocates Corporate Headquarters to Austin

February 11, 2019 (AUSTIN) – Affigen, a biotechnology company that develops personalized therapies targeting the signature proteins that uniquely identify tumors and other aberrant clonal cellular populations, today announced that it has relocated its corporate headquarters and research and development labs from St. Louis, MO to Austin, TX.

Citing an unrivaled innovation community, proximity to top universities, and a strong ability to recruit key talent, the move will empower Affigen to accelerate its future growth and product innovation here.

“Affigen is excited to become a part of the growing biotech innovation community in Austin,” said Carlos Santos, Ph.D., Founder and Chief Executive Officer. “There is no place like Austin in terms of the energy, culture, spirit of innovation and overall talent. Our presence in Austin will allow us to rapidly advance our cancer immunotherapy pipeline, recruit world-class biotechnology talent for our R&D and manufacturing activities, and to significantly advance the pace at which we can bring our novel immunotherapies to patients with cancer.“

Affigen has established research lab and office space within the Health Discovery Building at the University of Texas Dell Medical School. The company is hiring several scientists at its Austin facilities, expanding its pre-clinical research operations, and completing key partnerships as it works toward the launch of clinical trials for its lead programs in incurable leukemia and lymphoma.

The new headquarters are located at 1601 Trinity St., Building B, Suite 3.306, Austin, TX 78712.

About Affigen

Affigen (www.affigen.com) develops personalized therapies targeting the signature proteins that uniquely identify tumors and other aberrant clonal cellular populations. The Company’s growing team houses deep expertise in immuno-oncology, mass-personalized biomolecular engineering and complex therapeutic development, and is working to deliver a new class of therapeutics that maximize both anti-tumor activity and safety in patients with critically unmet medical needs. Affigen was founded in 2016 by Frameshift, a firm that launches and grows life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. Affigen and Frameshift are headquartered in Austin, TX.